Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus Gemcitabine in Advanced Soft-tissue Sarcomas
NCT06114004Phase 2Recruiting
- Sponsor
- SELNET
- Start
- Sep 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in leiomyosarcoma (LMS), malignant peripheral nerve sheath tumor (MPNST), sponsored by SELNET. Started Sep 2023; status: recruiting.
02
Drugs
selinexor
03
Conditions
leiomyosarcoma (LMS)malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on NCT06114004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06114004.